| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Association of Improved Outcomes and Phosphodiesterase-5 Inhibition During Contemporary LVAD Support
|
Jorde, Ulrich P.
|
|
|
10 |
2 |
p. 101-103
|
artikel
|
| 2 |
A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction
|
Tromp, Jasper
|
|
|
10 |
2 |
p. 73-84
|
artikel
|
| 3 |
Behavioral Benefits of COVID Lockdown for Heart Failure Patients
|
O’Connor, Christopher
|
|
|
10 |
2 |
p. 142-143
|
artikel
|
| 4 |
Can We Manage Presymptomatic TTR V142I Related Risk? ∗
|
Murray, Michael F.
|
|
|
10 |
2 |
p. 139-141
|
artikel
|
| 5 |
Early B-Type Natriuretic Peptide Change in HFrEF Patients Treated With Sacubitril/Valsartan
|
Myhre, Peder L.
|
|
|
10 |
2 |
p. 119-128
|
artikel
|
| 6 |
Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF
|
Docherty, Kieran F.
|
|
|
10 |
2 |
p. 104-118
|
artikel
|
| 7 |
Humanizing Policies and Allocation Systems
|
Bhimaraj, Arvind
|
|
|
10 |
2 |
p. 144
|
artikel
|
| 8 |
Personalizing Comprehensive Disease-Modifying Therapy
|
Bhatt, Ankeet S.
|
|
|
10 |
2 |
p. 85-88
|
artikel
|
| 9 |
Postimplant Phosphodiesterase-5 Inhibitor Use in Centrifugal Flow Left Ventricular Assist Devices
|
Xanthopoulos, Andrew
|
|
|
10 |
2 |
p. 89-100
|
artikel
|
| 10 |
Reply
|
Baran, David A.
|
|
|
10 |
2 |
p. 145
|
artikel
|
| 11 |
Transthyretin V142I Genetic Variant and Cardiac Remodeling, Injury, and Heart Failure Risk in Black Adults
|
Coniglio, Amanda C.
|
|
|
10 |
2 |
p. 129-138
|
artikel
|
Tijdschrift beschrijving